Your browser doesn't support javascript.
loading
Significant improvement of a nevus spilus-type congenital melanocytic nevus with oral selumetinib.
Berna, R; Hasbun, T; Adams, D; Moon, A T; Treat, J R.
Affiliation
  • Berna R; Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Hasbun T; Dermatology Department, Clínica Alemana de Santiago - Facultad de Medicina Universidad del Desarrollo and Hospital Exequiel González Cortés, Santiago, Chile.
  • Adams D; Division of General Pediatrics, Section of Pediatric Hematology and Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Moon AT; Division of General Pediatrics, Section of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Treat JR; Division of General Pediatrics, Section of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Pediatr Dermatol ; 2024 Jun 17.
Article in En | MEDLINE | ID: mdl-38886992
ABSTRACT
Giant congenital melanocytic nevi (GCMN) can be cosmetically significant and can lead to melanoma. There is no standard pharmacologic treatment for GCMN. We present the case of an 8-year-old female with kaposiform lymphangiomatosis caused by an NRAS mutation whose nevus spilus-type GCMN improved on oral selumetinib.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Pediatr Dermatol Year: 2024 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Pediatr Dermatol Year: 2024 Document type: Article Affiliation country: United States